Last reviewed · How we verify
Genz-682452
At a glance
| Generic name | Genz-682452 |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat (PHASE3)
- A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants (PHASE1)
- A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants (PHASE1)
- A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants (PHASE1)
- A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (PHASE2, PHASE3)
- A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation (PHASE2)
- Effect of Venglustat in Patients With Renal Impairment (PHASE1)
- Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Genz-682452 CI brief — competitive landscape report
- Genz-682452 updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI